Voronoi, with 'KRW 2 Trillion in License-Out Deals,' Receives Minister of Health and Welfare Commendation
2021.11.23
⚫ Global competitiveness in precision targeted therapies... Three license-out deals to U.S. pharmaceutical companies
Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a company specializing in the development of precision targeted therapies that has achieved 'cumulative license-out deals in the KRW 2 trillion range,' announced on the 23rd that it received the Minister of Health and Welfare Commendation at the awards for distinguished contributors held during the '2021 Health Industry Achievement Exchange Meeting' at the Dragon City Hotel in Yongsan, Seoul.
The award for distinguished contributors to health and medical technology commercialization is the award with the longest tradition and greatest prestige in the field of health and medical technology. It is presented to organizations and individuals who have contributed to promoting global technology commercialization and the development of Korea's health and medical industry through technology transactions and the promotion of innovative start-ups in the domestic and overseas health and medical fields. The recipients of the Minister of Health and Welfare Commendation (7 organizations and 7 individuals) were selected through a first round of screening by the Korea Health Industry Development Institute and a second round by the Ministry of Health and Welfare's merit review committee.
CEO Daekwon Kim of Voronoi said, "This is recognition of our achievement in completing four domestic and overseas license-out deals since last year. We will continue to further strengthen our global competitiveness while contributing to the development of Korea's bio industry through continued license-out deals."
The cumulative total milestone value of Voronoi's global license-out deals amounts to USD 1,790.5 million, or approximately KRW 2.1 trillion. In particular, the company has completed three license-out deals with pharmaceutical companies in the U.S., an advanced market.
In October of last year, Voronoi licensed out an EGFR Exon20 INS-targeting non-small cell lung cancer therapy to NASDAQ-listed ORIC Pharmaceuticals for up to USD 621 million, followed in August of this year by the license-out of a DYRK1A therapy for autoimmune and neuroinflammatory diseases to NASDAQ-listed Brickell Biotech for up to USD 323.5 million. More recently, it also licensed out an MPS1-targeting breast cancer and solid tumor therapy to Pyramid Biosciences of the U.S. for up to USD 846 million.
Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a company specializing in the development of precision targeted therapies that has achieved 'cumulative license-out deals in the KRW 2 trillion range,' announced on the 23rd that it received the Minister of Health and Welfare Commendation at the awards for distinguished contributors held during the '2021 Health Industry Achievement Exchange Meeting' at the Dragon City Hotel in Yongsan, Seoul.
The award for distinguished contributors to health and medical technology commercialization is the award with the longest tradition and greatest prestige in the field of health and medical technology. It is presented to organizations and individuals who have contributed to promoting global technology commercialization and the development of Korea's health and medical industry through technology transactions and the promotion of innovative start-ups in the domestic and overseas health and medical fields. The recipients of the Minister of Health and Welfare Commendation (7 organizations and 7 individuals) were selected through a first round of screening by the Korea Health Industry Development Institute and a second round by the Ministry of Health and Welfare's merit review committee.
CEO Daekwon Kim of Voronoi said, "This is recognition of our achievement in completing four domestic and overseas license-out deals since last year. We will continue to further strengthen our global competitiveness while contributing to the development of Korea's bio industry through continued license-out deals."
The cumulative total milestone value of Voronoi's global license-out deals amounts to USD 1,790.5 million, or approximately KRW 2.1 trillion. In particular, the company has completed three license-out deals with pharmaceutical companies in the U.S., an advanced market.
In October of last year, Voronoi licensed out an EGFR Exon20 INS-targeting non-small cell lung cancer therapy to NASDAQ-listed ORIC Pharmaceuticals for up to USD 621 million, followed in August of this year by the license-out of a DYRK1A therapy for autoimmune and neuroinflammatory diseases to NASDAQ-listed Brickell Biotech for up to USD 323.5 million. More recently, it also licensed out an MPS1-targeting breast cancer and solid tumor therapy to Pyramid Biosciences of the U.S. for up to USD 846 million.